Potassium Ion

Potassium Ion

SCHEMBL1819744

O=S(=O)([O-])c1ccc2ccccc2c1O.[K+]

nearest known ligand 0.49

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

AGTR1DHFRGABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTNR3C2PBP2XPTGS1PTGS2VKORC1blablaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAftsImrcAmrcBmrdApbp1apbp1bpbp2apbp2bpbp3polthyA

The experimentally established mechanism targets of Potassium Ion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTRB1 P17538 1/20 0.49
PTPN22 Q9Y2R2 1/20 0.48
LDHA P00338 1/20 0.46
ERN1 O75460 1/20 0.46
THRB P10828 1/20 0.45
NR4A1 P22736 1/20 0.45
CHEK1 O14757 1/20 0.44
CDK8 P49336 1/20 0.44
NEK2 P51955 1/20 0.44
LIMK1 P53667 1/20 0.44
F2 P00734 1/20 0.41
PRSS1 P07477 1/20 0.41
PRSS2 P07478 1/20 0.41
PRSS3 P35030 1/20 0.41
MEN1 O00255 1/20 0.41
MAPT P10636 1/20 0.41
KMT2A Q03164 1/20 0.41
HCRTR1 O43613 1/20 0.41
HTR6 P50406 1/20 0.41
MPL P40238 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Potassium Ion SCHEMBL31385186 1.00 CTRB1 (0.49) CTRB1PTPN22LDHAERN1THRB
SCHEMBL2880574 0.98 PTPN22 (0.50) CTRB1PTPN22LDHAERN1THRB
SCHEMBL8445295 0.96 CTRB1 (0.49) CTRB1PTPN22LDHAERN1THRB
SCHEMBL3169181 0.96 CTRB1 (0.49) CTRB1PTPN22LDHAERN1THRB
SCHEMBL339569 0.96 CTRB1 (0.49) CTRB1PTPN22LDHAERN1THRB
Hydrochloric Acid SCHEMBL27766336 0.81 CTRB1 (0.64) CTRB1PTPN22LDHAERN1CHEK1
SCHEMBL30383446 0.81 CTRB1 (0.64) CTRB1PTPN22LDHAERN1CHEK1
SCHEMBL88069 0.81 CTRB1 (0.64) CTRB1PTPN22LDHAERN1CHEK1
Potassium Ion SCHEMBL3628026 0.81 DNMT1 (0.44) CTRB1THRBNR4A1F2PRSS1
Potassium SCHEMBL2292044 0.79 CTRB1 (0.62) CTRB1PTPN22LDHAERN1CHEK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2218754-B1 POLYIMIDE COMPOSITE MATERIAL AND FILM OF THE SAME MITSUI CHEMICALS INC (JP) 2018-06-20 EP disclosed
US-9540487-B2 Polyimide composite material and film thereof MITSUI CHEMICALS, INC. (JP) 2017-01-10 US disclosed
US-8501981-B2 CXCR2 inhibitors SANOFI (FR) 2013-08-06 US disclosed
US-20110190309-A1 PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A Beta2-ADRENOCEPTOR AGONIST PULMAGEN THERAPEUTICS (SYNERGY) LIMITED (GB) 2011-08-04 US disclosed
EP-2315589-A1 PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A beta2-ADRENOCEPTOR AGONIST AstraZeneca AB (SE) 2011-05-04 EP disclosed
US-20100304160-A1 POLYIMIDE COMPOSITE MATERIAL AND FILM THEREOF MITSUI CHEMICALS, INC. (JP) 2010-12-02 US disclosed
EP-2218754-A1 POLYIMIDE COMPOSITE MATERIAL AND FILM OF THE SAME Mitsui Chemicals, Inc. (JP) 2010-08-18 EP disclosed
US-20100056547-A1 OPHTHALMIC COMPOSITIONS COMPRISING dDC ALLERGAN, INC. (US) 2010-03-04 US disclosed
WO-2009139707-A1 PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A SECOND ACTIVE INGREDIENT ASTRAZENECA AB (SE) 2009-11-19 WO disclosed
WO-2009139708-A1 PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A β2-ADRENOCEPTOR AGONIST ASTRAZENECA AB (SE) 2009-11-19 WO disclosed
EP-0137521-B1 INTEGRAL MULTILAYER ELEMENT FOR CHEMICAL ANALYSIS FUJI PHOTO FILM CO., LTD. (JP) 1989-09-27 EP disclosed
US-4781890-A LIGHT-BLOCKING LAYER, TITANIUM DIOXIDE; FLUORIDE SALT-FORMING CATION FUJI PHOTO FILM CO., LTD. (JP) 1988-11-01 US disclosed
EP-0243126-A2 Method of measuring hydrogen peroxide or of measuring an enzyme or biochemical substrate liberating the peroxide SANWA KAGAKU KENKYUSHO CO., LTD. (JP) 1987-10-28 EP disclosed
US-4681841-A CONSUMING OXYGEN OR GENERATING A PIGMENT; MEASUREMENT BY AN OXYGEN ELECTRODE OR COLORIMETRIC ASSAY TOYO JOZO KABUSHIKI KAISHA (JP) 1987-07-21 US disclosed
US-4675290-A CHROMATOGRAPHY OF THE ANILINE DYE PRODUCED BY COUPLING REACTI ON OF THE AMINE FORMED FROM THE AMIDE SUBSTRATE TOYO JOZO KABUSHIKI KAISHA (JP) 1987-06-23 US disclosed
US-4588836-A LEUCYL- OR GLUTAMYL-3,5-DIHALO-4-HYDROXYANILIDES TOYO JOZO KABUSHIKI KAISHA (JP) 1986-05-13 US disclosed
US-4551272-A Derivatives of dipeptide and their use in determining the activity of carboxypeptidase A FUJIREBIO KABUSHIKI KAISHA (JP) 1985-11-05 US disclosed
EP-0137521-A2 Integral multilayer element for chemical analysis FUJI PHOTO FILM CO., LTD. (JP) 1985-04-17 EP disclosed
US-4295853-A EXTRACTING LIPOPEROXIDE FROM BLOOD OR SERUM, OXIDIZABLE COLOR REAGENT, COMPOUND OF MULTIVALENT METAL WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 1981-10-20 US disclosed
US-4042335-A Integral element for analysis of liquids EASTMAN KODAK COMPANY (US) 1977-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190309-A1 PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A Beta2-ADRENOCEPTOR AGONIST ADRB2, ADRB1, ADRA2A CTRB1 2061/4885PTPN22 2960/4885LDHA 3667/4885
US-20100056547-A1 OPHTHALMIC COMPOSITIONS COMPRISING dDC PDE6C, DDC, PDE6H CTRB1 1122/4885PTPN22 906/4885LDHA 698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.